Literature DB >> 18065413

Tissue concentrations: do we ever learn?

Johan W Mouton1, Ursula Theuretzbacher, William A Craig, Paul M Tulkens, Hartmut Derendorf, Otto Cars.   

Abstract

Over the last decades, numerous papers have appeared--and still are appearing--that describe concentrations in tissues in an effort to predict the efficacy of an antimicrobial agent based on these concentrations and MICs for microorganisms. A common method is to use measurements of concentrations in tissue homogenates, comparing these with values derived from the corresponding blood samples and on that basis draw conclusions with respect to the potential clinical use of the drug. This approach is not justifiable for a number of reasons that includes both pharmacokinetic as well as pharmacodynamic causes. This way of presenting data with the derived conclusions is often misleading and may ultimately be harmful in patient care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18065413     DOI: 10.1093/jac/dkm476

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  121 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Authors:  Hans-Peter Lipp
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

3.  Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.

Authors:  Na Sun; Isis E Fernandez; Mian Wei; Yin Wu; Michaela Aichler; Oliver Eickelberg; Axel Walch
Journal:  Histochem Cell Biol       Date:  2015-12-08       Impact factor: 4.304

4.  Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.

Authors:  Pyry A J Välitalo; Koen Griffioen; Matthew L Rizk; Sandra A G Visser; Meindert Danhof; Gaori Rao; Piet H van der Graaf; J G Coen van Hasselt
Journal:  Pharm Res       Date:  2015-12-01       Impact factor: 4.200

5.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

6.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 7.  [Pharmacokinetics and pharmacodynamics of antibiotic therapy].

Authors:  S Beck; S G Wicha; C Kloft; M G Kees
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

8.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Authors:  Felipe K Hurtado; Benjamin Weber; Hartmut Derendorf; Guenther Hochhaus; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 10.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.